Indo-Bangla Pharmaceuticals Limited (DSE:IBP)
Bangladesh
· Delayed Price · Currency is BDT 13.10
-0.10 (-0.76%)
At close: Aug 13, 2025
DSE:IBP Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jul '22 Jul 1, 2022 | Jul '21 Jul 1, 2021 | Jun '20 Jun 30, 2020 | 2015 - 2019 |
| Revenue | 91.1 | 176.64 | 374.48 | 484.68 | 782.24 | 866.1 | Upgrade
|
| Revenue Growth (YoY) | -56.95% | -52.83% | -22.74% | -38.04% | -9.68% | 16.93% | Upgrade
|
| Cost of Revenue | 86.96 | 156.79 | 277.92 | 337.75 | 469.3 | 521.57 | Upgrade
|
| Gross Profit | 4.14 | 19.85 | 96.56 | 146.93 | 312.94 | 344.53 | Upgrade
|
| Selling, General & Admin | 33.99 | 43.61 | 67.88 | 111.13 | 139.64 | 132.71 | Upgrade
|
| Operating Expenses | 33.99 | 43.61 | 67.88 | 111.13 | 139.64 | 132.71 | Upgrade
|
| Operating Income | -29.85 | -23.76 | 28.68 | 35.8 | 173.3 | 211.82 | Upgrade
|
| Interest Expense | -4.48 | -4.4 | -5.23 | -4.88 | -3.81 | - | Upgrade
|
| Interest & Investment Income | - | - | - | - | - | 2.16 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.07 | 0.25 | 0.42 | 0.8 | 0.63 | 3.03 | Upgrade
|
| EBT Excluding Unusual Items | -34.26 | -27.91 | 23.87 | 31.72 | 170.11 | 217.01 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 0.7 | - | -0.77 | - | Upgrade
|
| Pretax Income | -34.26 | -27.91 | 24.57 | 31.72 | 169.34 | 217.01 | Upgrade
|
| Income Tax Expense | 11.75 | 13.07 | 16.17 | 6.55 | 34.62 | 60.76 | Upgrade
|
| Net Income | -46.01 | -40.98 | 8.41 | 25.17 | 134.73 | 156.24 | Upgrade
|
| Net Income to Common | -46.01 | -40.98 | 8.41 | 25.17 | 134.73 | 156.24 | Upgrade
|
| Net Income Growth | - | - | -66.60% | -81.31% | -13.77% | 0.66% | Upgrade
|
| Shares Outstanding (Basic) | 143 | 116 | 116 | 116 | 114 | 114 | Upgrade
|
| Shares Outstanding (Diluted) | 143 | 116 | 116 | 116 | 114 | 114 | Upgrade
|
| Shares Change (YoY) | 28.19% | - | - | 2.17% | - | 13.37% | Upgrade
|
| EPS (Basic) | -0.32 | -0.35 | 0.07 | 0.22 | 1.18 | 1.37 | Upgrade
|
| EPS (Diluted) | -0.32 | -0.35 | 0.07 | 0.22 | 1.18 | 1.37 | Upgrade
|
| EPS Growth | - | - | -66.60% | -81.71% | -13.77% | -11.22% | Upgrade
|
| Free Cash Flow | 13.76 | 23.64 | 42.92 | 47.6 | -49.39 | -133.47 | Upgrade
|
| Free Cash Flow Per Share | 0.10 | 0.20 | 0.37 | 0.41 | -0.43 | -1.17 | Upgrade
|
| Dividend Per Share | - | 0.010 | - | 0.100 | 0.400 | - | Upgrade
|
| Dividend Growth | - | - | - | -75.00% | - | - | Upgrade
|
| Gross Margin | 4.55% | 11.24% | 25.79% | 30.31% | 40.01% | 39.78% | Upgrade
|
| Operating Margin | -32.77% | -13.45% | 7.66% | 7.39% | 22.15% | 24.46% | Upgrade
|
| Profit Margin | -50.51% | -23.20% | 2.25% | 5.19% | 17.22% | 18.04% | Upgrade
|
| Free Cash Flow Margin | 15.10% | 13.38% | 11.46% | 9.82% | -6.31% | -15.41% | Upgrade
|
| EBITDA | -8.67 | 4.78 | 67.05 | 74.93 | 209.2 | 240.72 | Upgrade
|
| EBITDA Margin | -9.52% | 2.71% | 17.90% | 15.46% | 26.74% | 27.79% | Upgrade
|
| D&A For EBITDA | 21.18 | 28.54 | 38.36 | 39.13 | 35.9 | 28.9 | Upgrade
|
| EBIT | -29.85 | -23.76 | 28.68 | 35.8 | 173.3 | 211.82 | Upgrade
|
| EBIT Margin | -32.77% | -13.45% | 7.66% | 7.39% | 22.15% | 24.46% | Upgrade
|
| Effective Tax Rate | - | - | 65.79% | 20.64% | 20.44% | 28.00% | Upgrade
|
| Advertising Expenses | - | 0.24 | 0.77 | 4.19 | 7.02 | 7.11 | Upgrade
|
Updated Dec 24, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.